Skip to main content

Nuvation Bio Inc

For the period ended Mar 31, 2024. Filed May 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 14, 2024

NUVB$4.20-3.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Stockholders' Equity

(Unaudited, In thousands, except share data)

For the Three Months Ended March 31, 2024 and 2023

Common Stock andAdditional Paid-in Capital · Accumulated · AccumulatedOtherComprehensive · TotalStockholders'
Class A SharesClass B SharesAmountDeficitIncome (Loss)Equity
Balance, December 31, 2023218,046,2191,000,000$947,745$(342,804)$181$605,122
Exercise of stock options37,000—21——21
Stock-based compensation——5,041——5,041
Net loss———(14,792)—(14,792)
Other comprehensive loss————(1,350)(1,350)
Balance, March 31, 2024218,083,2191,000,000$952,807$(357,596)$(1,169)$594,042
Common Stock andAdditional Paid-in Capital · Accumulated · AccumulatedOtherComprehensive · TotalStockholders'
Class A SharesClass B SharesAmountDeficitLossEquity
Balance, December 31, 2022217,632,6991,000,000$927,604$(267,002)$(5,526)$655,076
Exercise of stock options171,023—298——298
Stock-based compensation——4,837——4,837
Net loss———(21,726)—(21,726)
Other comprehensive income————2,5882,588
Balance, March 31, 2023217,803,7221,000,000$932,739$(288,728)$(2,938)$641,073
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.